- Trials with a EudraCT protocol (90)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
90 result(s) found for: Wagner's disease.
Displaying page 1 of 5.
EudraCT Number: 2010-023277-19 | Sponsor Protocol Number: | Start Date*: 2011-05-05 |
Sponsor Name:Med. Univ. Wien, Univ. Klinik für Dermatologie | ||
Full Title: CD20-Immunotargeting in Stage IV Melanoma Patients- A Prospective, Open Label, Two-Period Pilot Study to Evaluate Overall Tumor Responsive Rate | ||
Medical condition: Patients suffering from early stage melanoma have a good chance of recovery whereas the 5-year survival rate of patients with metastasized melanomas (stage III and stage IV) is less than 10% for th... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-005125-30 | Sponsor Protocol Number: V1.1 | Start Date*: 2008-11-20 |
Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Dermatologie, Abteilung für Immundermatologie | ||
Full Title: Rituximab (Mabthera) in metastatic melanoma | ||
Medical condition: metastatic melanoma patients, clinical stage IIIc/IV ( AJCC2002), disease free | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-004410-13 | Sponsor Protocol Number: 3401 | Start Date*: 2008-03-12 | ||||||||||||||||
Sponsor Name:Institute od Rheumatology Prague | ||||||||||||||||||
Full Title: A PROSPECTIVE, RANDOMISED, ASSESSOR-BLIND, MULTICENTER STUDY OF EFFICACY AND SAFETY OF COMBINED TREATMENT OF METHOTREXATE + GLUCOCORTICOIDS VERSUS GLUCOCORTICOIDS ALONE IN PATIENTS WITH POLYMYOSITI... | ||||||||||||||||||
Medical condition: active polymyositis, dermatomyositis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) SE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004787-10 | Sponsor Protocol Number: C0251008 | Start Date*: 2022-03-07 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS ≥18 AND ≤80 WITH ACTIVE DERMATOMYOSITIS. | |||||||||||||
Medical condition: Dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) ES (Ongoing) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002758-31 | Sponsor Protocol Number: ECD01 | Start Date*: 2006-12-22 | |||||||||||
Sponsor Name:EPOPLUS GmbH & Co.KG | |||||||||||||
Full Title: A randomized, double-blind, multi-centre, placebo-controlled, parallel-group study to examine the efficacy and safety of low dose Epoetin beta on wound healing in diabetes patients with foot ulcer | |||||||||||||
Medical condition: wound healing in diabetes patients with foot ulcer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006426-43 | Sponsor Protocol Number: IPAX-Linz-01 | Start Date*: 2022-02-16 |
Sponsor Name:Kepler Universitätsklinikum Linz Neuromed Campus | ||
Full Title: An open label, single arm monocentric phase II study to evaluate safety, tolerability, and preliminary efficacy of carrier-added 4-L- [131I]iodophenylalanine (131I-IPA), administered as sequential ... | ||
Medical condition: Previously confirmed histological diagnosis of malignant brain tumours (glioma), with current clinical or imaging evidence for first or second recurrence | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005772-34 | Sponsor Protocol Number: CL2-78989-010 | Start Date*: 2013-06-17 | ||||||||||||||||
Sponsor Name:Institut de Recherches Internationales Servier (IRIS) | ||||||||||||||||||
Full Title: A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every 4 weeks over 24 weeks in the treatment of patients with polymyositis o... | ||||||||||||||||||
Medical condition: Polymyositis / Dermatomyositis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) SE (Completed) DE (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005966-35 | Sponsor Protocol Number: KKS/INNERE_A/AML2006 | Start Date*: 2006-07-24 |
Sponsor Name:Universitätsklinikum Münster | ||
Full Title: A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in elderly patients with newly diagnosed AML | ||
Medical condition: Patients older than 60 years with newly diagnosed acute myeloid leukemia (AML) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000449-15 | Sponsor Protocol Number: DIONYSIUS | Start Date*: 2020-12-11 |
Sponsor Name:Amsterdam University Medical Centers, location AMC | ||
Full Title: Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently? | ||
Medical condition: Ischemic diabetic foot ulcers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002710-31 | Sponsor Protocol Number: SCGAM-02 | Start Date*: 2018-08-20 | |||||||||||
Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H | |||||||||||||
Full Title: DOUBLE-BLIND, RANDOMIZED, PLACEBO- CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH DERMATOMYOSITIS. | |||||||||||||
Medical condition: Dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000391-15 | Sponsor Protocol Number: AIFA-2016-02364869 | Start Date*: 2018-06-05 | |||||||||||||||||||||
Sponsor Name:Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia | |||||||||||||||||||||||
Full Title: Multicentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis | |||||||||||||||||||||||
Medical condition: Myositis (dermatomyositis [DM] or polymyositis [PM]) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006311-21 | Sponsor Protocol Number: CBAF312A2202 | Start Date*: 2009-07-28 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis | ||||||||||||||||||
Medical condition: Polymyositis and dermatomyositis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004228-41 | Sponsor Protocol Number: C0251002 | Start Date*: 2021-07-28 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | |||||||||||||
Medical condition: Dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) HU (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000898-83 | Sponsor Protocol Number: ADN016 | Start Date*: 2021-11-10 | |||||||||||
Sponsor Name:ADIENNE SA | |||||||||||||
Full Title: A phase II, randomized, double-blind, placebo-controlled, two-period, crossover trial to assess the efficacy and safety of begelomab in combination with standard steroid and/or immunosuppressant th... | |||||||||||||
Medical condition: Dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001799-39 | Sponsor Protocol Number: CBAF312X2206 | Start Date*: 2013-09-26 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis. | |||||||||||||
Medical condition: Active dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001398-34 | Sponsor Protocol Number: BMMNC_PTA_001 | Start Date*: 2016-06-15 | |||||||||||
Sponsor Name:Institut klinické a experimentální medicíny | |||||||||||||
Full Title: A prospective, randomized study to assess the effect of autologous bone marrow-derived mononuclear cell therapy and its combination with percutaneous transluminal angioplasty (PTA) in comparison wi... | |||||||||||||
Medical condition: In our study, the effect of autologous cell therapy (ACT) will be compared with repeated percutaneous transluminal angioplasty (re-PTA) in patients with diabetic foot and then will be compared the ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001397-15 | Sponsor Protocol Number: BMMNC_CLI_001 | Start Date*: 2016-06-15 | |||||||||||
Sponsor Name:Institut klinické a experimentální medicíny | |||||||||||||
Full Title: A prospective, randomized study to compare the effect on tissue oxygenation and clinical outcome of autologous bone marrow-derived mononuclear cell therapy with standard treatment in patients with ... | |||||||||||||
Medical condition: Autologous cell therapy (ACT) is new technique for patients with critical limb ischemia and diabetic foot (DF). In our study, the effect of ACT and also the repetitive treatment will be compared wi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015957-20 | Sponsor Protocol Number: ARTEMIS | Start Date*: 2010-02-16 | ||||||||||||||||
Sponsor Name:Karolinska University Hospital | ||||||||||||||||||
Full Title: Abatacept treatment in polymyositis and dermatomyositis | ||||||||||||||||||
Medical condition: polymyositis and dermatomyositis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Ongoing) CZ (Completed) GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005721-25 | Sponsor Protocol Number: Lifetime | Start Date*: 2023-07-05 |
Sponsor Name:Univeristy Hospital Tuebingen | ||
Full Title: SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial | ||
Medical condition: The study will include adult male and female patients with an early stage of chronic kidney disease (CKD stage G1A2/G2A2) and prediabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000137-52 | Sponsor Protocol Number: IFN-K-005-DM | Start Date*: 2016-07-26 | |||||||||||
Sponsor Name:Neovacs SA | |||||||||||||
Full Title: A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects with Dermatomyositis. | |||||||||||||
Medical condition: Dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
